Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy Remains the No. 1 Cancer Centre in France and Europe
The excellence of Gustave Roussy has once again been recognised by the American magazine Newsweek, which has ranked the Institute as the leading cancer centre in France and in Europe, and among the very best worldwide, following the publication of the World’s Best Specialised Hospitals 2026 ranking.
Published on
The excellence of Gustave Roussy has once again been recognised by the American magazine Newsweek, which has ranked the Institute as the leading cancer centre in France and in Europe, and among the very best worldwide, following the publication of the World’s Best Specialised Hospitals 2026 ranking.
Published annually by Newsweek in collaboration with Statista, the World’s Best Specialised Hospitals 2026 ranking is based on the results of an online survey of tens of thousands of healthcare experts worldwide and takes into account quality indicators reported by patients.
“This ranking highlights France’s ability to shine on the scientific stage. Gustave Roussy secures its place in the world’s Top 10, at sixth position, competing with centres with vastly larger budgets, thereby demonstrating the Institute’s capacity for innovation and the talent of its teams. This result, which is a source of pride for all our staff, is also a call to strengthen public and private investment so that French research can compete with the leading American and Asian oncology centres,” says Professor Fabrice Barlesi, Chief Executive Officer of Gustave Roussy.
In this context of heightened global competition with institutions that enjoy budgets far exceeding those available in France and unparalleled human resources, Gustave Roussy’s continued presence in the world’s Top 10 – ranking first in France and first in Europe – is an exceptional achievement. It is evidence of the innovative strength and talent of French teams and of the unwavering commitment of the Institute’s staff to deliver the highest quality of care to all patients, alongside top-level research with major societal impact. Researchers and clinicians continue to work towards their goal of curing 80 % of patients with cancer by 2040.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
